Published in TB and Outbreaks Week, November 18th, 2003
The deal provides Chiron with an exclusive royalty-bearing license while enabling the HPA to continue its research and development activities in the field. In return, Chiron will pay the HPA a signing-on fee, with other terms of the agreement including milestone payments for product development through to market and a royalty income from any...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week